摘要
目的观察厄洛替尼治疗晚期非小细胞肺癌的疗效及不良反应。方法32例经放、化疗治疗失败的非小细胞肺癌患者,其中6例肿瘤局限于胸腔内,26例已有远处转移,厄洛替尼剂量为每天150mg,口服,每天1次,直到肿瘤进展或因不良反应不能耐受而中止治疗。结果32例患者中,完全缓解1例,部分缓解9例,稳定13例,进展9例,全组有效率为31.3%,疾病控制率为71.9%,中位生存期7.8月,1年生存率为45.3%。主要不良反应是皮疹和腹泻,不需要特殊处理。结论厄洛替尼对放、化疗失败的晚期非小细胞肺癌有较好的治疗效果,且不良反应轻。
Objective To evaluate the efficacy and toxicity of erlotinib in patients with advanced non-small cell lung cancer （NSCLC）.Methods Thirty-two patients with NSCLC failed prior chemotherapy and radiotherapy were applied.Prior to erlotinib therapy,26 patients were in stage Ⅳ,6 patients in stage ⅢB.Erlotinib was administered orally at 150 mg,once a day until cancer progressed or severe toxicity occured.Results Among the 32 patients,1 patient got complete response （CR）,9 partial response（PR）,13 stable disease（SD）,and 9 progression disease（PD）.The total response rate was 31.3% and disease control rate including both tumor response and stable disease was 71.9 %.The median survival time was 7.8 months.The l year survival rate was 45.3%.The main toxicity of erlotinib was skin toxicity （rash） and diarrha with no need for further treatment.Conclusion Erlotinib is effective and tolerable for the patients with NSCLC who failed prior chemotherapy and radiotherapy.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2010年第4期461-462,共2页
Cancer Research on Prevention and Treatment
关键词
厄洛替尼
非小细胞肺癌
靶向治疗
Erlotinib
Non-small cell lung cancer
Target therapy
